ELAN STOCK UPDATE: Elanco Animal Health Investors that Lost Money when the … – Newsfile Corp.

Elanco Animal Health Investors Alert: Lawsuit Filed by BFA Law for Stock Plummet

If you’re an investor who recently experienced a loss due to a sharp drop in Elanco Animal Health’s stock price, you may want to take note of this latest development. Bleichmar Fonti & Auld LLP, a prominent securities law firm, has filed a lawsuit against Elanco Animal Health Incorporated (NYSE:ELAN) and some of its top executives over potential violations of federal securities laws.

The lawsuit specifically focuses on the recent decline in Elanco’s stock price following negative news about the company’s drug development pipeline. Elanco had been eagerly awaiting FDA approval for two key treatments, Zenrelia for a type of dermatitis in dogs, and Credelio Quattro, an oral parasiticide for fleas, ticks, and internal parasites. However, on June 27, 2024, Elanco announced that neither drug was expected to receive FDA approval as initially anticipated, with additional concerns raised about the safety labeling for Zenrelia.

In response to this news, Elanco’s stock plummeted by more than 21% in a single day. Investors who suffered losses as a result of this drop are now being invited to seek additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. There is a deadline of December 6, 2024, for investors to apply to lead the case in court.

The lawsuit, filed in the U.S. District Court of Maryland under the caption Barpar v. Elanco Animal Health Incorporated, et al., No. 24-cv-02912, alleges that Elanco and its executives may have misled investors about the status of their FDA drug approvals, potentially leading to financial losses for shareholders.

If you’re an investor who holds Elanco Animal Health Incorporated (NYSE: ELAN) shares, you may have legal options available to you and are encouraged to consider submitting your information to the law firm. The firm operates on a contingency fee basis, meaning there is no upfront cost to you to pursue legal action.

For more information on this lawsuit and the legal options available to investors, visit https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated or reach out directly to Ross Shikowitz at ross@bfalaw.com or 212-789-3619.

Bleichmar Fonti & Auld LLP is a well-respected law firm known for its work in securities class actions and shareholder litigation. With a track record of successful outcomes for investors, the firm operates under a principle of seeking justice for those who have been impacted by potential securities violations.

This announcement is not a guarantee of future results, but rather an invitation for affected investors to explore their legal options. For more details on the firm and its legal team, visit https://www.bfalaw.com.